Studying Tumor Blood Vessel Growth on a Microfluidic Chip
Author Information
Author(s): Skubal Magdalena, Larney Benedict Mc, Phung Ngan Bao, Desmaras Juan Carlos, Dozic Abdul Vehab, Volpe Alessia, Ogirala Anuja, Machado Camila Longo, Djibankov Jakob, Ponomarev Vladimir, Grimm Jan
Primary Institution: Memorial Sloan Kettering Cancer Center, New York, NY, USA
Hypothesis
Can a microfluidic chip effectively model tumor neovascularization and evaluate vascular targeted therapies?
Conclusion
The microfluidic chip model allows for rapid and precise assessment of vascular targeted therapies, significantly reducing the time needed compared to traditional animal models.
Supporting Evidence
- The microfluidic chip allowed for real-time observation of blood vessel formation.
- Bevacizumab treatment disrupted the vascular network formed by endothelial cells.
- The model provided results in weeks compared to months in traditional animal studies.
- Endothelial cells sprouted towards the tumor spheroids, mimicking natural angiogenesis.
- PSMA expression was induced in endothelial cells in the presence of tumor spheroids.
Takeaway
Researchers created a tiny chip that mimics how tumors grow blood vessels, helping them test new cancer treatments faster than before.
Methodology
The study used a microfluidic chip to co-culture human endothelial cells and metastatic renal cell carcinoma spheroids to observe tumor-induced angiogenesis and test the effects of bevacizumab.
Potential Biases
Potential bias in the interpretation of results due to the controlled environment of the microfluidic chip compared to in vivo conditions.
Limitations
The model does not replicate the full complexity of the tumor microenvironment and only includes cancer and endothelial cells without immune components.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website